The Association between Blood Lipids and Systemic Lupus Erythematosus: A Two-Sample Mendelian Randomization Research.

We evaluated the causal effects of blood lipid levels on systemic lupus erythematosus with a two-sample Mendelian randomization analysis. Independent single-nucleotide polymorphisms related to blood lipids levels ( < 5 × 10) were selected as instrumental variables (IVs) from a published genome-wide association study (GWAS). SLE GWAS analysis that included 4036 cases and 6959 controls of European ancestry provided the related roles between instrumental variables and result (SLE). The causal effects were evaluated with two-sample Mendelian randomization (MR) analyses. According to the inverse-variance weighted approaches, genes predictive of increased LDL cholesterol (OR: 1.131; 95% CI: 0.838, 1.528; = 0.420), HDL cholesterol (OR: 1.093; 95% CI: 0.884, 1.352; = 0.412), triglycerides (OR: 0.903; 95% CI: 0.716, 1.137; = 0.384), Apolipoprotein A-I (OR: 0.854; 95% CI: 0.680, 1.074; = 0.177), and Apolipoprotein B (OR: 0.933; 95% CI: 0.719, 1.211; = 0.605) were not causally related to the risk of SLE, consistent with multivariate Mendelian randomization analysis. The reverse-MR analyses showed no massive causal roles between SLE and LDL cholesterol (OR: 0.998; 95% CI: 0.994, 1.001; = 0.166) as well as Apolipoprotein B (OR: 0.998; 95% CI: 0.994, 1.001; = 0.229). Nevertheless, a causal role of SLE in decreasing HDL cholesterol (OR: 0.993; 95% CI: 0.988, 0.997; = 0.002), triglycerides (OR: 0.996; 95% CI: 0.993, 0.999; = 0.010), and Apolipoprotein A-I (OR: 0.995; 95% CI: 0.990, 0.999; = 0.026) was validated to some extent. Our study found no causal association between abnormal blood lipids and SLE nor a causal effect between SLE and LDL cholesterol as well as Apolipoprotein B. Nevertheless, some evidence showed that SLE exerted a causal effect on lowering HDL cholesterol, Apolipoprotein A-I, and triglyceride levels.